Invitae - NVTA Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 4 sell ratings and 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View NVTA analyst ratings or view top-rated stocks.

11 Wall Street analysts have issued 12-month price targets for Invitae's shares. Their NVTA share price forecasts range from $1.75 to $8.50. On average, they anticipate the company's stock price to reach $4.58 in the next year. This suggests a possible upside of 254.9% from the stock's current price.
View analysts price targets for NVTA or view top-rated stocks among Wall Street analysts.

Invitae's stock was trading at $1.86 at the start of the year. Since then, NVTA stock has decreased by 30.6% and is now trading at $1.29.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023.
View our NVTA earnings forecast.

Invitae Co. (NYSE:NVTA) announced its quarterly earnings results on Tuesday, February, 28th. The medical research company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.21. The medical research company earned $122.45 million during the quarter, compared to the consensus estimate of $120.98 million. Invitae had a negative trailing twelve-month return on equity of 59.44% and a negative net margin of 601.64%. The firm's revenue for the quarter was down 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.81) EPS.

ETFs with the largest weight of Invitae (NYSE:NVTA) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Direxion Moonshot Innovators ETF (MOON), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Telemedicine & Digital Health ETF (EDOC), Global X Genomics & Biotechnology ETF (GNOM), AXS Green Alpha ETF (NXTE), ARK Genomic Revolution ETF (ARKG) and ARK Innovation ETF (ARKK).

Invitae issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.00M-, compared to the consensus revenue estimate of $516.11 million.

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Invitae's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.15%), Sumitomo Mitsui Trust Holdings Inc. (7.10%), Nikko Asset Management Americas Inc. (7.10%), Geode Capital Management LLC (1.76%), Charles Schwab Investment Management Inc. (0.72%) and Gilder Gagnon Howe & Co. LLC (0.62%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends.

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVTA stock can currently be purchased for approximately $1.29.

Invitae (NYSE:NVTA) has a market capitalization of $316.36 million and generates $516.30 million in revenue each year. The medical research company earns $-3,106,290,000.00 in net income (profit) each year or ($13.35) on an earnings per share basis.

The company employs 1,700 workers across the globe.

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com.